



April 2022 Apple Health PDL changes (Medicaid)

On April 1, 2022, Apple Health (Medicaid) contracted managed care (MCO) and fee-for-service (FFS) plans made changes on the Apple Health Preferred Drug List to make some brand name products preferred and their associated generic products non-preferred with prior authorization required.

After considering feedback received from the provider community, Apple Health (Medicaid) will be reversing the changes made to the generic products listed in the table below. Brand name products will continue to be preferred. This change will be made retroactive to dates of service on or after April 1, 2022.

Apple Health (Medicaid) contracted MCO and FFS plans will make these changes as soon as possible, but no later than June 1, 2022.

Generic Products that will change to preferred by June 1, 2022

AMPHETAMINE/DEXTROAMPHETAMINE
METHYLPHENIDATE HYDROCHLORIDE ER
DIAZEPAM RECTAL GEL
CARBAMAZEPINE ER
DIVALPROEX SODIUM
CLONIDINE HCL
BUDESONIDE/FORMOTEROL FUMARATE DIHYDRATE
FLUTICASONE PROPIONATE/SALMETEROL
FLUTICASONE PROPIONATE/SALMETEROL DISKUS
MESALAMINE ER
MESALAMINE DR

If you have any questions, please email applehealthpharmacypolicy@hca.wa.gov.

Thank you for your continued service to Molina members.